Compare NVNI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVNI | IVVD |
|---|---|---|
| Founded | 2019 | 2020 |
| Country | Brazil | United States |
| Employees | 618 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | NVNI | IVVD |
|---|---|---|
| Price | $1.29 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 82.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $6.67 | $143.48 |
| Revenue Next Year | $26.67 | $25.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.14 | $0.46 |
| 52 Week High | $4.94 | $3.07 |
| Indicator | NVNI | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 52.23 |
| Support Level | $1.10 | $1.41 |
| Resistance Level | $1.64 | $2.01 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 45.67 | 62.92 |
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.